# "InDACtion" vs "3+7" Induction in AML

> **NCT02172872** · PHASE3 · UNKNOWN · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 606 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** standard combination chemotherapy
- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT02172872
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11-28
- **Primary completion:** 2022-03-07
- **Final completion:** 2023-12
- **Target enrollment:** 606 (ACTUAL)
- **Last updated:** 2023-02-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172872, ""InDACtion" vs "3+7" Induction in AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02172872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*